Tripegfilgrastim is named as an intervention in 3 current clinical trials in our Canada, Israel, Australia, Mexico, Egypt and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Children's Oncology Group (1). The most-studied condition is Central Nervous System Nongerminomatous Germ Cell Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368 · ClinicalTrials.gov ↗ · Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma
|
Phase 2 | Recruiting | Children's Oncology Group | Canada, Australia, Israel |
|
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
NCT06135896 · ClinicalTrials.gov ↗ · Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
|
Phase 2 | Recruiting | National Cancer Center, Korea | South Korea |
|
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
|
Phase 3 | Active, closed | National Cancer Institute (NCI) | Canada, Mexico, Israel, Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Children's Oncology Group | 1 |
| National Cancer Institute (NCI) | 1 |
| National Cancer Center, Korea | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 1 |
| Clinical trials in Israel | 2 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Egypt | 1 | 0 |
| Clinical trials in South Korea | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada, Israel, Australia, Mexico, Egypt and South Korea registers name Tripegfilgrastim as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Canada, 1 with sites in Israel, 1 with sites in Australia and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Children's Oncology Group (1), National Cancer Institute (NCI) (1) and National Cancer Center, Korea (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tripegfilgrastim works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tripegfilgrastim works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tripegfilgrastim (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.